Compare COLM & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLM | TVTX |
|---|---|---|
| Founded | 1938 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 1997 | 2013 |
| Metric | COLM | TVTX |
|---|---|---|
| Price | $55.24 | $27.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $60.86 | $36.25 |
| AVG Volume (30 Days) | 484.2K | ★ 1.0M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $3,042,478,000.00 | N/A |
| Revenue This Year | $3.73 | $44.62 |
| Revenue Next Year | $3.04 | $31.76 |
| P/E Ratio | $17.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.48 | $12.91 |
| 52 Week High | $77.97 | $42.13 |
| Indicator | COLM | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 46.81 |
| Support Level | $53.96 | $26.72 |
| Resistance Level | $58.08 | $31.47 |
| Average True Range (ATR) | 1.52 | 1.09 |
| MACD | -0.34 | 0.02 |
| Stochastic Oscillator | 17.17 | 57.83 |
Columbia Sportswear Co makes outdoor and active-lifestyle apparel, footwear, equipment, and accessories that it sells under four primary brands: Columbia, Sorel, Mountain Hardwear, and prAna. The majority of sales are in the United States, but the company also has remarkable sales in its three other geographic segments: Latin American and Asia-Pacific; Europe, Middle East, and Africa; and Canada. The majority of sales are through wholesale channels, including sporting goods and department stores, but the company also operates its own branded stores in each of its geographic segments. It sources products from around the world and uses contract manufacturers outside the United States, predominantly in Asia to manufacture its various products.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.